2d
Zacks Investment Research on MSNAmgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
2d
Zacks.com on MSNWhy the Market Dipped But Amgen (AMGN) Gained TodayAmgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Amgen is expected to post earnings of $4.18 per ...
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results